PE First-90-Days Pricing Diagnostic: The Checklist That Finds the Gaps

You are 30 days post-close. You have read the board materials, met the management team, and reviewed the 100-day plan. You have a number the fund needs to return and a hold period to return it in.

Now comes the work that most operating partners delay because it feels like finance, not operations: understanding what is actually happening to price.

This is a checklist. Work through it in order. Each item builds on the previous one and the sequence matters.

The Real Cost

Ninety days of pricing ambiguity at a portco is not neutral. Every deal that closes during those 90 days embeds whatever discount norms currently exist in the culture. If your average discount rate is 19 percent and you spend 90 days understanding the business before addressing it, you have added 90 days of 19 percent discounting to your annual recurring revenue (ARR) base.

On a portco closing 30 deals per quarter at $50,000 list annual contract value (ACV), that is 30 deals times $9,500 in realized discount per deal, or $285,000 of ARR you will never recover from those cohorts. At a 6x exit multiple, you have spent 90 days accruing a $1.7 million hole in your exit valuation before you have done a single thing wrong.

Move fast on the diagnostic. The cost of delay is real and it is specific.

The Framework: A Three-Stage Checklist

Stage 1: Baseline the commercial reality (Days 1 to 30)

First, run the pocket price waterfall. Ask the CFO for every contract signed in the last 12 months, with list price, negotiated price, any post-signature credits or concessions, and realized revenue in the first four quarters. This single document tells you more about commercial health than any board deck.

Second, map the discount exception log. Who can approve what. How many exceptions were approved above the stated ceiling. Which sales reps have the highest exception rates. This tells you whether the problem is structural or cultural.

Third, build the cohort net revenue retention (NRR) table. Net revenue retention broken out by acquisition year, plan tier, and segment. You are looking for the inflection points: where does NRR drop below 100 percent and why. Is it contraction, churn, or both?

Fourth, document every pricing change in the last 36 months. For each change, record the before-and-after retention in the affected cohort. This is your evidence base for whether this company's customers respond to price changes or not.

Stage 2: Run eight customer interviews (Days 15 to 45)

Do not skip this step and do not delegate it to the management team. You need to hear directly from customers, and the questions are specific.

Ask each customer: "If the price of this product increased 20 percent at your next renewal, what would happen?" And: "What would it cost your organization to replace this product with an alternative?" And: "What part of this product's value is difficult to quantify in your internal budgeting process?"

Those three questions will tell you your effective pricing ceiling, your switching cost, and the value attribution gaps that are making it hard to raise prices. Run eight interviews and you will have a pattern. Run fewer and you are guessing.

Stage 3: Build the earnings before interest, taxes, depreciation and amortization (EBITDA) impact model (Days 45 to 90)

Take the pocket price waterfall and model two scenarios. First: what happens to annualized ARR and EBITDA if you close 50 percent of the discount gap through governance alone, with no price increase? Second: what happens if you raise list prices 10 percent in the segment with the highest switching cost and tightest competitive positioning?

Both scenarios should show a range of outcomes based on what your customer interviews told you about price sensitivity. The output is not a recommendation. It is a decision framework that lets you and management agree on the hypothesis you are going to test and the governance controls you will put in place to test it cleanly.

The Failure Case

An operating partner at a mid-market private equity (PE) fund took over a portco at month four of the hold, after the prior operating partner had departed. The pricing diagnostic had been on the 100-day plan but had never been completed.

By month 16, the portco had a new pricing tier, a revised deal desk policy, and a discount floor. What it did not have was baseline data. Because no one had run the pocket price waterfall in the first 90 days, there was no clean before-state to compare against.

When the board asked whether the pricing initiative had improved realized ACV, the answer was: probably, but we cannot measure it with confidence. That uncertainty made the initiative impossible to defend at exit. The buyer ran their own analysis on trailing twelve months and concluded that pricing governance was still inconsistent. The exit valuation was haircut by 8 percent on revenue quality grounds.

The diagnostic would have taken three weeks in month one. The cost of not doing it was measured at exit in millions.

What to Do This Week

Start with item one: the pocket price waterfall. If you are post-close and do not have this document, request it from the CFO today. If there is resistance to providing it, that resistance is itself a finding.

Once you have it, spend two hours working through the numbers before you share it with anyone else. Identify the three largest sources of discount gap by segment and deal type. That analysis is the foundation for everything else in the checklist.

To run this diagnostic against FintastIQ's portco benchmark data, use the FintastIQ Pricing Diagnostic. It will tell you whether your gap is typical for a company at your stage or whether it signals a structural problem.

For more on what the diagnostic should feed into, see our post on building a hypothesis-led pricing plan for PE value creation and our guide on the hidden costs of bad pricing decisions during the hold period.